Agenus Inc.
Agenus Inc. is dedicated to harnessing the power of the immune system to develop therapies with curative intent for individuals living with cancer. The company focuses on immuno-oncology (I-O) therapeutics, including antibody therapeutics, adoptive cell therapies, adjuvants, and vaccines, with a mission to expand the patient population benefiting from immunotherapy through innovative combination approaches.
Industries
Nr. of Employees
large (251-1000)
Patents
Products
Clinical-stage antibody therapeutic programs (immuno-oncology)
A portfolio of clinical-stage monoclonal antibody programs focused on immuno-oncology indications, including combination regimens evaluated in colorectal and ovarian cancers.
Adoptive cell therapy and vaccine/adjuvant programs
R&D-stage adoptive cell therapy programs and vaccine/adjuvant platforms developed via subsidiary operations or dedicated internal units.
Clinical-stage antibody therapeutic programs (immuno-oncology)
A portfolio of clinical-stage monoclonal antibody programs focused on immuno-oncology indications, including combination regimens evaluated in colorectal and ovarian cancers.
Adoptive cell therapy and vaccine/adjuvant programs
R&D-stage adoptive cell therapy programs and vaccine/adjuvant platforms developed via subsidiary operations or dedicated internal units.
Services
Provision of medical information, contact request handling, and support for investigator-sponsored clinical trials and access to investigational medicines.
Transfer of manufacturing assets and technology transfer activities to partner organizations to support biologics supply and scale-up.
Structuring of strategic collaborations, licensing arrangements and co-development partnerships to accelerate program development and provide commercial optionality.
Provision of medical information, contact request handling, and support for investigator-sponsored clinical trials and access to investigational medicines.
Transfer of manufacturing assets and technology transfer activities to partner organizations to support biologics supply and scale-up.
Structuring of strategic collaborations, licensing arrangements and co-development partnerships to accelerate program development and provide commercial optionality.
Expertise Areas
- Immuno-oncology antibody therapeutics
- Antibody Fc engineering
- Clinical trial management and execution
- Neoadjuvant oncology development
Key Technologies
- Monoclonal antibody engineering
- Fc-region (effector) engineering
- CTLA-4 targeted immunotherapy
- Combination immunotherapy regimens